A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Clinical trial NCT06305767 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06305767
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-28
- Primary completion
- 2027-04-23
- Enrollment
- 230
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.